expresspharmaJanuary 29, 2021
Tag: Elucidata , IvyCap , Hyperplane
Biomedical molecular data firm Elucidata said it has raised $5 million (around Rs 36 crore) in a funding round led by IvyCap Ventures.
The pre-Series A funding round also saw participation from Hyperplane Venture Capital and a few angel investors, Elucidata said in a statement.
The funding will enable the company to capitalise on its position as a leading provider of structured biomedical molecular data to the life sciences industry, it added.
“In the pharma industry, biomedical data of drug discovery is increasing in diversity and volume at a rapid rate. In this scenario, it gives us immense pleasure to collaborate with a team which is driven by a vision of drug discovery and pharma R&D,” said Vikram Gupta, Founder and Managing Partner of IvyCap Ventures.
Abhishek Jha, Co-founder and CEO of Elucidata said, “The strong backing from IvyCap Ventures and Hyperplane would amplify our ability to help our partners improve in their data-driven drug discovery”.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: